Skip to main content

Table 1 Defined quality deficiencies for SafeBoosC-III randomised clinical trial

From: Central data monitoring in the multicentre randomised SafeBoosC-III trial – a pragmatic approach

1. Proportion of participants without an early and a late cranial ultrasound scan (including only participants alive after 35 days of life)
2. Late initiation of cerebral oximetry monitoring (0 to 6 h from birth)
3. Proportion of participants where cerebral oximetry was stopped prematurely (including only participants alive after 72 h of life)
4. Proportion of participants where consent was withdrawn or declined by the parents
5. Proportion of participants with a severe brain injury but no cranial ultrasound scan
6. Proportion of participants with post-haemorrhagic ventricular dilatation or cerebral atrophy but no late cranial ultrasound scan
7. Proportion of participants in the control group that underwent unblinded cerebral oximetry monitoring